Fluctuations in weight, either a loss or a gain, occurred significantly more often in people with Parkinson’s disease than in those without the progressive neurodegenerative disorder, a study has found. Weight loss in Parkinson’s patients was associated with a faster progression of motor and cognitive declines over a five-year…
News
A miniature antibody-like molecule called a nanobody effectively broke up toxic alpha-synuclein aggregates that are characteristic of Parkinson’s disease, and prevented the spread of these aggregates in the brains of mice in a disease model. The novel construct was described in the journal Nature Communications, in the study, “…
Treatment with Kynmobi (apomorphine hydrochloride), an approved under-the-tongue therapy for “off” episodes in Parkinson’s disease, does not substantially alter heartbeat dynamics at approved doses, according to new clinical trial data. The study, “A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s…
Researchers have developed a new method of temporarily opening the selective blood-brain barrier (BBB) to allow therapeutic molecules greater access to the brain. Difficulties in developing molecules that can cross this barrier have long hindered the development of treatments for neurological diseases, like Parkinson’s disease. The technique could now…
Buntanetap, Annovis Bio’s investigational oral treatment for neurodegenerative diseases, was safe and showed effectiveness in people with early-stage Parkinson’s disease, a presentation of Phase 2 trial data showed, paving the way for Phase 3 testing in a larger patient group. The U.S. Food and Drug Administration recently gave the…
The Parkinson’s Foundation invested $1.1 million in two fellowships programs aimed at giving neurologists and nurse practitioners more specialized and expert training in Parkinson’s disease (PD). Specifically, the investment supports the Institutional Movement Disorder (IMDS) Fellowship Program for neurologists and the newly opened Nurse Practitioner (NP) Fellowship in Movement Disorders.
A new project by scientists at the University of Michigan (UM) aims to design a prototype autonomous vehicle that’s specifically designed to help meet the needs of people living with Parkinson’s disease. The project, called “Inclusive Design in Shared Autonomous Vehicles for People with Parkinson’s Disease,” is being funded…
A Parkinson’s-associated variant in the LRRK2 gene affects the gene’s activity in a single group of brain cells: microglia, the resident immune cells of the brain. “Our study demonstrates that cell type should be considered when evaluating the role of noncoding variation in disease pathogenesis [development],” the researchers wrote. The…
A more extensive biopsy involving larger tissue samples taken from the gastrointestinal (GI) tract of people with Parkinson’s disease improves the ability to identify alpha-synuclein protein clumping, researchers in a small study reported. These findings support more extensive GI biopsies as a diagnostic tool for Parkinson’s and other…
ZyVersa Therapeutics announced that a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support work into IC 100 as a potential antibody-based therapy for Parkinson’s disease. Robert Keane, PhD, and Juan Pablo de Rivero Vaccari, PhD, professors at the University of…
Recent Posts
- How being a skilled queen bee prepared me for Parkinson’s caregiving
- Grants fund tests of portable devices in Parkinson’s speech therapy
- Light therapy device seen to brighten life quality for those with Parkinson’s
- When early memories of Parkinson’s came full circle
- FDA grants advanced therapy status to Parkinson’s cell treatment